Low maternal concentrations of soluble vascular endothelial growth factor receptor-2 in preeclampsia and small for gestational age

Tinnakorn Chaiworapongsa; Roberto Romero; Francesca Gotsch; Jimmy Espinoza; Jyh Kae Nien; Luis Goncalves; Samuel Edwin; Yeon Mee Kim; Offer Erez; Juan Pedro Kusanovic; Beth L. Pineles; Zoltan Papp; Sonia Hassan

doi:10.1080/14767050701831397

Low maternal concentrations of soluble vascular endothelial growth factor receptor-2 in preeclampsia and small for gestational age

Tinnakorn Chaiworapongsa, Roberto Romero, Francesca Gotsch, Jimmy Espinoza, Jyh Kae Nien, Luis Goncalves, Samuel Edwin, Yeon Mee Kim, Offer Erez, Juan Pedro Kusanovic, Beth L. Pineles, Zoltan Papp, Sonia Hassan

Research output: Contribution to journal › Article › peer-review

64 Scopus citations

Abstract

Objectives. Preeclampsia is considered an anti-angiogenic state. A role for the anti-angiogenic factors soluble vascular endothelial growth factor receptor-1 (sVEGFR-1) and soluble endoglin in preeclampsia has been proposed. Soluble vascular endothelial growth factor receptor-2 (sVEGFR-2) has been detected in human plasma, and the recombinant form of this protein has anti-angiogenic activity. There is a paucity of information about maternal plasma sVEGFR-2 concentrations in patients with preeclampsia and those without preeclampsia with small for gestational age (SGA) fetuses. This study was conducted to determine whether: (1) plasma sVEGFR-2 concentration changes throughout pregnancy; and (2) preeclampsia and SGA are associated with abnormalities in the maternal plasma concentration of sVEGFR-2. Study design. This cross-sectional study included non-pregnant women (n = 40), women with normal pregnancies (n = 135), women with an SGA fetus (n = 53), and women with preeclampsia (n = 112). SGA was defined as an ultrasound-estimated fetal weight below the 10th percentile for gestational age that was confirmed by neonatal birth weight. Plasma concentrations of sVEGFR-2 were determined by ELISA. Results. (1) There was no significant difference in the mean plasma concentration of sVEGFR-2 between non-pregnant women and those with normal pregnancies (p = 0.8); (2) patients with preeclampsia and those without preeclampsia with SGA fetuses had a lower mean plasma concentration of sVEGFR-2 than that of women with normal pregnancies (p < 0.001 for both); and (3) there was no significant difference in the mean plasma concentration of sVEGFR-2 between patients with preeclampsia and those without preeclampsia with SGA (p = 0.9). Conclusions. Preeclampsia and SGA are associated with low plasma concentrations of sVEGFR-2. One interpretation of the findings is that plasma sVEGFR-2 concentration could reflect endothelial cell function.

Original language	English
Pages (from-to)	41-52
Number of pages	12
Journal	Journal of Maternal-Fetal and Neonatal Medicine
Volume	21
Issue number	1
DOIs	https://doi.org/10.1080/14767050701831397
State	Published - 14 Jan 2008
Externally published	Yes

Keywords

Intrauterine growth restriction
KDR
Preeclampsia
Pregnancy
Small for gestational age
sVEGFR-2

ASJC Scopus subject areas

Pediatrics, Perinatology, and Child Health
Obstetrics and Gynecology

Access to Document

10.1080/14767050701831397

Cite this

Chaiworapongsa, T., Romero, R., Gotsch, F., Espinoza, J., Nien, J. K., Goncalves, L., Edwin, S., Kim, Y. M., Erez, O., Kusanovic, J. P., Pineles, B. L., Papp, Z., & Hassan, S. (2008). Low maternal concentrations of soluble vascular endothelial growth factor receptor-2 in preeclampsia and small for gestational age. Journal of Maternal-Fetal and Neonatal Medicine, 21(1), 41-52. https://doi.org/10.1080/14767050701831397

@article{b2be7db44f004782abc776ae1a8431f2,

title = "Low maternal concentrations of soluble vascular endothelial growth factor receptor-2 in preeclampsia and small for gestational age",

abstract = "Objectives. Preeclampsia is considered an anti-angiogenic state. A role for the anti-angiogenic factors soluble vascular endothelial growth factor receptor-1 (sVEGFR-1) and soluble endoglin in preeclampsia has been proposed. Soluble vascular endothelial growth factor receptor-2 (sVEGFR-2) has been detected in human plasma, and the recombinant form of this protein has anti-angiogenic activity. There is a paucity of information about maternal plasma sVEGFR-2 concentrations in patients with preeclampsia and those without preeclampsia with small for gestational age (SGA) fetuses. This study was conducted to determine whether: (1) plasma sVEGFR-2 concentration changes throughout pregnancy; and (2) preeclampsia and SGA are associated with abnormalities in the maternal plasma concentration of sVEGFR-2. Study design. This cross-sectional study included non-pregnant women (n = 40), women with normal pregnancies (n = 135), women with an SGA fetus (n = 53), and women with preeclampsia (n = 112). SGA was defined as an ultrasound-estimated fetal weight below the 10th percentile for gestational age that was confirmed by neonatal birth weight. Plasma concentrations of sVEGFR-2 were determined by ELISA. Results. (1) There was no significant difference in the mean plasma concentration of sVEGFR-2 between non-pregnant women and those with normal pregnancies (p = 0.8); (2) patients with preeclampsia and those without preeclampsia with SGA fetuses had a lower mean plasma concentration of sVEGFR-2 than that of women with normal pregnancies (p < 0.001 for both); and (3) there was no significant difference in the mean plasma concentration of sVEGFR-2 between patients with preeclampsia and those without preeclampsia with SGA (p = 0.9). Conclusions. Preeclampsia and SGA are associated with low plasma concentrations of sVEGFR-2. One interpretation of the findings is that plasma sVEGFR-2 concentration could reflect endothelial cell function.",

keywords = "Intrauterine growth restriction, KDR, Preeclampsia, Pregnancy, Small for gestational age, sVEGFR-2",

author = "Tinnakorn Chaiworapongsa and Roberto Romero and Francesca Gotsch and Jimmy Espinoza and Nien, \{Jyh Kae\} and Luis Goncalves and Samuel Edwin and Kim, \{Yeon Mee\} and Offer Erez and Kusanovic, \{Juan Pedro\} and Pineles, \{Beth L.\} and Zoltan Papp and Sonia Hassan",

year = "2008",

month = jan,

day = "14",

doi = "10.1080/14767050701831397",

language = "English",

volume = "21",

pages = "41--52",

journal = "Journal of Maternal-Fetal and Neonatal Medicine",

issn = "1476-7058",

publisher = "Taylor and Francis Ltd.",

number = "1",

}

Chaiworapongsa, T, Romero, R, Gotsch, F, Espinoza, J, Nien, JK, Goncalves, L, Edwin, S, Kim, YM, Erez, O, Kusanovic, JP, Pineles, BL, Papp, Z & Hassan, S 2008, 'Low maternal concentrations of soluble vascular endothelial growth factor receptor-2 in preeclampsia and small for gestational age', Journal of Maternal-Fetal and Neonatal Medicine, vol. 21, no. 1, pp. 41-52. https://doi.org/10.1080/14767050701831397

TY - JOUR

T1 - Low maternal concentrations of soluble vascular endothelial growth factor receptor-2 in preeclampsia and small for gestational age

AU - Chaiworapongsa, Tinnakorn

AU - Romero, Roberto

AU - Gotsch, Francesca

AU - Espinoza, Jimmy

AU - Nien, Jyh Kae

AU - Goncalves, Luis

AU - Edwin, Samuel

AU - Kim, Yeon Mee

AU - Erez, Offer

AU - Kusanovic, Juan Pedro

AU - Pineles, Beth L.

AU - Papp, Zoltan

AU - Hassan, Sonia

PY - 2008/1/14

Y1 - 2008/1/14

N2 - Objectives. Preeclampsia is considered an anti-angiogenic state. A role for the anti-angiogenic factors soluble vascular endothelial growth factor receptor-1 (sVEGFR-1) and soluble endoglin in preeclampsia has been proposed. Soluble vascular endothelial growth factor receptor-2 (sVEGFR-2) has been detected in human plasma, and the recombinant form of this protein has anti-angiogenic activity. There is a paucity of information about maternal plasma sVEGFR-2 concentrations in patients with preeclampsia and those without preeclampsia with small for gestational age (SGA) fetuses. This study was conducted to determine whether: (1) plasma sVEGFR-2 concentration changes throughout pregnancy; and (2) preeclampsia and SGA are associated with abnormalities in the maternal plasma concentration of sVEGFR-2. Study design. This cross-sectional study included non-pregnant women (n = 40), women with normal pregnancies (n = 135), women with an SGA fetus (n = 53), and women with preeclampsia (n = 112). SGA was defined as an ultrasound-estimated fetal weight below the 10th percentile for gestational age that was confirmed by neonatal birth weight. Plasma concentrations of sVEGFR-2 were determined by ELISA. Results. (1) There was no significant difference in the mean plasma concentration of sVEGFR-2 between non-pregnant women and those with normal pregnancies (p = 0.8); (2) patients with preeclampsia and those without preeclampsia with SGA fetuses had a lower mean plasma concentration of sVEGFR-2 than that of women with normal pregnancies (p < 0.001 for both); and (3) there was no significant difference in the mean plasma concentration of sVEGFR-2 between patients with preeclampsia and those without preeclampsia with SGA (p = 0.9). Conclusions. Preeclampsia and SGA are associated with low plasma concentrations of sVEGFR-2. One interpretation of the findings is that plasma sVEGFR-2 concentration could reflect endothelial cell function.

AB - Objectives. Preeclampsia is considered an anti-angiogenic state. A role for the anti-angiogenic factors soluble vascular endothelial growth factor receptor-1 (sVEGFR-1) and soluble endoglin in preeclampsia has been proposed. Soluble vascular endothelial growth factor receptor-2 (sVEGFR-2) has been detected in human plasma, and the recombinant form of this protein has anti-angiogenic activity. There is a paucity of information about maternal plasma sVEGFR-2 concentrations in patients with preeclampsia and those without preeclampsia with small for gestational age (SGA) fetuses. This study was conducted to determine whether: (1) plasma sVEGFR-2 concentration changes throughout pregnancy; and (2) preeclampsia and SGA are associated with abnormalities in the maternal plasma concentration of sVEGFR-2. Study design. This cross-sectional study included non-pregnant women (n = 40), women with normal pregnancies (n = 135), women with an SGA fetus (n = 53), and women with preeclampsia (n = 112). SGA was defined as an ultrasound-estimated fetal weight below the 10th percentile for gestational age that was confirmed by neonatal birth weight. Plasma concentrations of sVEGFR-2 were determined by ELISA. Results. (1) There was no significant difference in the mean plasma concentration of sVEGFR-2 between non-pregnant women and those with normal pregnancies (p = 0.8); (2) patients with preeclampsia and those without preeclampsia with SGA fetuses had a lower mean plasma concentration of sVEGFR-2 than that of women with normal pregnancies (p < 0.001 for both); and (3) there was no significant difference in the mean plasma concentration of sVEGFR-2 between patients with preeclampsia and those without preeclampsia with SGA (p = 0.9). Conclusions. Preeclampsia and SGA are associated with low plasma concentrations of sVEGFR-2. One interpretation of the findings is that plasma sVEGFR-2 concentration could reflect endothelial cell function.

KW - Intrauterine growth restriction

KW - KDR

KW - Preeclampsia

KW - Pregnancy

KW - Small for gestational age

KW - sVEGFR-2

UR - https://www.scopus.com/pages/publications/37849018744

U2 - 10.1080/14767050701831397

DO - 10.1080/14767050701831397

M3 - Article

AN - SCOPUS:37849018744

SN - 1476-7058

VL - 21

SP - 41

EP - 52

JO - Journal of Maternal-Fetal and Neonatal Medicine

JF - Journal of Maternal-Fetal and Neonatal Medicine

IS - 1

ER -

Low maternal concentrations of soluble vascular endothelial growth factor receptor-2 in preeclampsia and small for gestational age

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this